NasdaqGM:CLXT

Stock Analysis Report

Executive Summary

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Calyxt's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.8%

CLXT

2.0%

US Biotechs

1.0%

US Market


1 Year Return

-59.0%

CLXT

-5.5%

US Biotechs

8.0%

US Market

Return vs Industry: CLXT underperformed the US Biotechs industry which returned -5.5% over the past year.

Return vs Market: CLXT underperformed the US Market which returned 8% over the past year.


Shareholder returns

CLXTIndustryMarket
7 Day11.8%2.0%1.0%
30 Day-22.7%-2.2%-0.07%
90 Day-44.7%-2.0%-1.0%
1 Year-59.0%-59.0%-4.6%-5.5%10.4%8.0%
3 Yearn/a15.4%11.4%46.2%36.7%
5 Yearn/a-3.1%-7.8%64.3%46.2%

Price Volatility Vs. Market

How volatile is Calyxt's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Calyxt undervalued compared to its fair value and its price relative to the market?

2.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CLXT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CLXT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CLXT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CLXT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLXT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLXT is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Calyxt forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

27.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLXT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLXT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLXT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLXT's revenue (65% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CLXT's revenue (65% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLXT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Calyxt performed over the past 5 years?

-36.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CLXT is unprofitable, and losses have increased over the past 5 years at a rate of -36.8% per year.

Accelerating Growth: Unable to compare CLXT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: CLXT has a negative Return on Equity (-40.81%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CLXT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CLXT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Calyxt's financial position?


Financial Position Analysis

Short Term Liabilities: CLXT's short term assets ($79.3M) exceeds its short term liabilities ($5.0M)

Long Term Liabilities: CLXT's short term assets (79.3M) exceeds its long term liabilities (18.4M)


Debt to Equity History and Analysis

Debt Level: CLXT is debt free.

Reducing Debt: CLXT had no debt 5 years ago.


Balance Sheet

Inventory Level: CLXT has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CLXT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLXT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CLXT has sufficient cash runway for 1.525498 years if free cash flow continues to reduce at historical rates of -30.3% each year.


Next Steps

Dividend

What is Calyxt's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.3%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CLXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CLXT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CLXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLXT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLXT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Calyxt's salary, the management and board of directors tenure and is there insider trading?

0.7yrs

Average management tenure


CEO

Jim Blome (56yo)

1yrs

Tenure

US$5,229,684

Compensation

Mr. James A. Blome, also known as Jim, is the Chief Executive Officer of Calyxt since October 1, 2018. He was President and Chief Executive Officer of Bayer CropScience LP till September 2018. He serves as ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jim's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Jim's compensation with company performance.


Management Age and Tenure

0.7yrs

Average Tenure

47.5yo

Average Age

Experienced Management: CLXT's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

54yo

Average Age

Experienced Board: CLXT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$46,12927 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$17.87
SellUS$44,71321 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$17.32
SellUS$42,80215 Mar 19
James Blome
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares2,582
Max PriceUS$16.58
SellUS$332,50415 Mar 19
Yves Ribeill
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares19,980
Max PriceUS$17.39

Ownership Breakdown


Management Team

  • Jim Blome (56yo)

    Chief Executive Officer

    • Tenure: 1yrs
    • Compensation: US$5.23m
  • Dan Voytas (56yo)

    Founder & Chief Science Officer

    • Tenure: 0yrs
    • Compensation: US$282.67k
  • Simon Harnest

    VP of Corporate Strategy & Finance

    • Tenure: 0yrs
  • Eric Dutang (45yo)

    Principal Accounting Officer

    • Tenure: 1.3yrs
  • Manoj Sahoo (44yo)

    Chief Business Development & Supply Chain Officer

    • Tenure: 2.6yrs
    • Compensation: US$407.49k
  • Keith Blanks

    Senior Vice President of Sales & Marketing

    • Tenure: 0.08yrs
  • Bill Koschak (50yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Debra Frimerman (39yo)

    General Counsel

    • Tenure: 0.7yrs
  • Travis Frey

    Chief Technology Officer

    • Tenure: 0.4yrs
  • Trina Lundblad

    Director of Communications

    • Tenure: 0.3yrs

Board Members

  • Yves Ribeill (59yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$3.17m
  • Jonathan Fassberg (53yo)

    Independent Director

    • Tenure: 1.2yrs
    • Compensation: US$534.36k
  • Chris Neugent (58yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$528.11k
  • Kim Nelson (51yo)

    Independent Director

    • Tenure: 0.8yrs
  • André Choulika (54yo)

    Chairman of the Board

    • Tenure: 9.2yrs
    • Compensation: US$65.00k
  • Anna Kozicz-Stankiewicz (44yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$50.00k
  • Philippe Dumont (68yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$65.00k

Company Information

Calyxt, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calyxt, Inc.
  • Ticker: CLXT
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$168.610m
  • Shares outstanding: 32.87m
  • Website: https://www.calyxt.com

Number of Employees


Location

  • Calyxt, Inc.
  • 2800 Mount Ridge Road
  • Roseville
  • Minnesota
  • 55113
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLXTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2017

Biography

Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 00:44
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.